Wang Shao-Mei, Sun Ze-Qiang, Li Hong-Yun, Wang Jin, Liu Qing-Yong
Center for Kidney Disease, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, China.
Department of Urinary Surgery, Qianfoshan Hospital Affiliated to Shandong University, 16766 Jingshi Road, Jinan, Shandong 250014, China.
Comput Math Methods Med. 2015;2015:313740. doi: 10.1155/2015/313740. Epub 2015 Oct 12.
The objective of this work is to identify dysregulated genes and pathways of ccRCC temporally according to systematic tracking of the dysregulated modules of reweighted Protein-Protein Interaction (PPI) networks.
Firstly, normal and ccRCC PPI network were inferred and reweighted based on Pearson correlation coefficient (PCC). Then, we identified altered modules using maximum weight bipartite matching and ranked them in nonincreasing order. Finally, gene compositions of altered modules were analyzed, and pathways enrichment analyses of genes in altered modules were carried out based on Expression Analysis Systematic Explored (EASE) test.
We obtained 136, 576, 693, and 531 disrupted modules of ccRCC stages I, II, III, and IV, respectively. Gene composition analyses of altered modules revealed that there were 56 common genes (such as MAPK1, CCNA2, and GSTM3) existing in the four stages. Besides pathway enrichment analysis identified 5 common pathways (glutathione metabolism, cell cycle, alanine, aspartate, and glutamate metabolism, arginine and proline metabolism, and metabolism of xenobiotics by cytochrome P450) across stages I, II, III, and IV.
We successfully identified dysregulated genes and pathways of ccRCC in different stages, and these might be potential biological markers and processes for treatment and etiology mechanism in ccRCC.
本研究的目的是通过对重新加权的蛋白质-蛋白质相互作用(PPI)网络失调模块进行系统追踪,来确定肾透明细胞癌(ccRCC)随时间变化的失调基因和通路。
首先,基于皮尔逊相关系数(PCC)推断并重新加权正常和ccRCC的PPI网络。然后,我们使用最大权重二分匹配法识别改变的模块,并按降序对其进行排名。最后,分析改变模块的基因组成,并基于表达分析系统探索(EASE)测试对改变模块中的基因进行通路富集分析。
我们分别获得了ccRCC I、II、III和IV期的136、576、693和531个破坏模块。对改变模块的基因组成分析表明,四个阶段共有56个共同基因(如MAPK1、CCNA2和GSTM3)。此外,通路富集分析确定了I、II、III和IV期共有5条共同通路(谷胱甘肽代谢、细胞周期、丙氨酸、天冬氨酸和谷氨酸代谢、精氨酸和脯氨酸代谢以及细胞色素P450对外源生物的代谢)。
我们成功地确定了ccRCC不同阶段的失调基因和通路,这些可能是ccRCC治疗和病因机制的潜在生物标志物和过程。